Enlivex Therapeutics Ltd. ENLV

$ 0.85 -12.81%

Annual report 2023
added 11-09-2024

Enlivex Therapeutics Ltd. Balance Sheet 2011-2024 | ENLV

Annual Balance Sheet Enlivex Therapeutics Ltd.

	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-	-	-	-	-	-	-7.29 M	-10.6 M	-5.55 M	-146 K	-
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	686 K	4.19 M	5.39 M	499 K	298 K	198 K	-	-	70 K	-	-	-	-
Total Current Liabilities	6.06 M	6.61 M	4.72 M	4.37 M	5.98 M	1.13 M	460 K	1.93 M	2.51 M	2.28 M	-	-	-
Total Liabilities	6.75 M	10.8 M	10.1 M	4.87 M	6.28 M	1.33 M	-	-	2.58 M	2.28 M	131 K	81 K	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-112 M	-83 M	-52 M	-37.5 M	-25.7 M	-16.3 M	-45.8 M	-39.8 M	-23.8 M	-8.42 M	-1.4 M	-229 K	-
Total Assets	36.8 M	67.6 M	95.1 M	40.4 M	17.6 M	11 M	3.62 M	10.6 M	20.5 M	33 M	5.69 M	156 K	-
Cash and Cash Equivalents	-	-	-	5.67 M	3.95 M	377 K	3.53 M	6.87 M	262 K	10.6 M	270 K	146 K	-
Book Value	30.1 M	56.8 M	85 M	35.5 M	11.3 M	9.71 M	3.62 M	10.6 M	17.9 M	30.7 M	5.56 M	75 K	-
Total Shareholders Equity	30.1 M	56.8 M	85 M	35.5 M	11.3 M	9.71 M	8.49 M	2.81 M	5.46 M	30.7 M	175 K	75 K	-

All numbers in USD currency

Quarterly Balance Sheet Enlivex Therapeutics Ltd.

	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	-	-	-	405 K	-	499 K	-	236 K	-	298 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	5.39 M	-	405 K	-	499 K	-	236 K	-	298 K	-	-	-	198 K	-	-	-	351 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	-	-	-	10.1 M	-	4.98 M	-	4.87 M	-	5.24 M	-	6.28 M	-	-	-	1.33 M	-	-	-	1.05 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-	-	-	-	-52 M	-	-43.8 M	-	-37.5 M	-	-29.5 M	-	-25.7 M	-	-	-	-16.3 M	-	-	-	-45.8 M	-	-	-	-39.8 M	-	-	-	-23.8 M	-	-	-	-8.42 M	-	-	-	-1.4 M	-	-	-	-	-	-	-	-	-	-	-
Total Assets	-	-	-	-	95.1 M	-	95.2 M	-	40.4 M	-	35.4 M	-	17.6 M	-	-	-	11 M	-	-	-	3.62 M	-	-	-	10.6 M	-	-	-	20.5 M	-	-	-	33 M	-	-	-	306 K	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	-	-	-	-	11.2 M	-	12.6 M	53.2 M	5.67 M	-	10.2 M	24.8 M	3.95 M	-	16.1 M	-	9.74 M	-	-	-	9.03 M	-	-	-	3.04 M	-	-	-	7.29 M	-	-	-	10.6 M	-	-	-	270 K	-	-	-	146 K	-	-	-	-	-	-	-
Book Value	-	-	-	-	85 M	-	90.2 M	-	35.5 M	-	30.2 M	-	11.3 M	-	-	-	9.71 M	-	-	-	2.58 M	-	-	-	10.6 M	-	-	-	20.5 M	-	-	-	33 M	-	-	-	306 K	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	-	-	-	-	85 M	-	90.2 M	-	35.5 M	-	30.2 M	-	11.3 M	-	-	-	9.71 M	-	-	-	8.49 M	-	-	-	2.81 M	-	-	-	17.9 M	-	-	-	30.7 M	-	-	-	175 K	-	-	-	75 K	-	-	-	-	-	-	-

All numbers in USD currency